CARLSBAD, Calif., Sept. 21,
2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:
TYRA), a clinical-stage biotechnology company focused on developing
next-generation precision medicines that target large opportunities
in Fibroblast Growth Factor Receptor (FGFR) biology, today
announced that TYRA will deliver oral presentations on TYRA-300 for
achondroplasia at the American Society for Bone and Mineral
Research (ASBMR) and the American Society of Human Genetics (ASHG)
2023 annual meetings.
ASBMR is taking place October 13-16,
2023, in Vancouver, BC,
Canada and ASHG is taking place
November 1-5, 2023, in Washington, DC.
ASBMR presentation details:
Title: "TYRA-300 Demonstrates Significant Increases in
Growth and Bone Length in a Mouse Model of FGFR3-Related Skeletal
Dysplasia"
Presentation Number: 1077
Session: Oral Presentations: Skeletal Development and Disease
Presentation Date/Time: Sunday, October 15,
2023, 10:00 AM
TYRA Presenter: Ronald Swanson,
Ph.D., Chief Scientific Officer
ASHG presentation details:
Title: "TYRA-300 Demonstrates Significant Increases in
Growth and Bone Length in a Mouse Model of FGFR3-Related Skeletal
Dysplasia"
Session: Oral Presentations: Precision prescription: The
therapeutic potential of ASOs and small molecules for genetic
disorders
Presentation Date/Time: Friday, November 3,
2023, 12:00 PM
TYRA Presenter: Jacqueline H.
Starrett, PhD, Associate Director, In Vivo Pharmacology
More information on the annual meetings can be found below:
- ASBMR 2023 Annual Meeting - American Society for Bone and
Mineral Research
- ASHG 2023 Scientific Program and Schedule of Events - ASHG
The presentation materials will be made available via
the For Investors page on the Investor section of the
TYRA website.
About TYRA-300
TYRA-300 is the Company's lead precision medicine program
stemming from its in-house SNÅP platform. TYRA-300 is an
investigational, oral, FGFR3-selective inhibitor currently in
development for the treatment of cancer and skeletal dysplasias
including achondroplasia. TYRA-300 is being evaluated in a
multi-center, open label Phase 1/2 clinical study, SURF301
(Study in Untreated
and Resistant FGFR3+ Advanced Solid
Tumors). SURF301 (NCT05544552) was designed to determine the
optimal and maximum tolerated doses (MTD) and the recommended Phase
2 dose (RP2D) of TYRA-300, as well as to evaluate the preliminary
antitumor activity of TYRA-300. SURF301 is currently enrolling
adults with advanced urothelial carcinoma and other solid
tumors with FGFR3 gene alterations. In skeletal dysplasias,
TYRA-300 has demonstrated positive preclinical results and the
Company expects to submit an IND for the initiation of a Phase 2
clinical study in pediatric achondroplasia in 2024.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's initial
focus is on applying its accelerated small molecule drug discovery
engine to develop therapies in targeted oncology and genetically
defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us
on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-oral-presentations-on-tyra-300-for-achondroplasia-at-the-asbmr-and-ashg-2023-annual-meetings-301934286.html
SOURCE Tyra Biosciences
